VIR

Vir BiotechnologyC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$16.00

Analysis reference price unavailable

Analysis 2026-05-08 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$10.50

Analysis reference price unavailable

Analysis 2026-05-08 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$6.00

Analysis reference price unavailable

Analysis 2026-05-08 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-05-08

AI commentary

This was a post-earnings follow-up run anchored on the May 6, 2026 company release and May 7, 2026 10-Q. The company source confirmed better runway, Astellas close, and several dated pipeline checkpoints, but checked sources did not provide a reliable consensus revenue/EPS comparison and visible post-print analyst revision flow was sparse, so the earnings read-through remains only moderately stronger rather than thesis-changing. With the anchor close at $9.27 on May 7, the market had not yet delivered a decisive re-rating despite improved cash visibility and preserved catalyst density.

RankAlpha Sentiment Codex - 2026-05-08

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-27eventEASL CHD update is the next clean data checkpointHigh impact

Vir said it will present additional Phase 2 SOLSTICE data for tobevibart plus elebsiran in chronic hepatitis delta at the EASL Congress on May 27-30, 2026, after highlighting Week 72 and Week 96 antiviral activity in its Q1 update; this is the nearest meaningful efficacy checkpoint for the lead liver program [#8-K-2026-05-06] [#10-Q-2026-05-07].

2026-06-30catalystQ2 Astellas cash inflow and longer runway reduce financing pressureMedium impact

Q1 results showed $809.3 million of cash, cash equivalents and investments at March 31, 2026, excluding the combined $315 million Astellas upfront payment and equity investment expected in Q2 2026, while management said current plans fund operations into the second half of 2028; that improves balance-sheet durability but is likely only partly incremental because the collaboration has already been disclosed [#8-K-2026-05-06] [#10-Q-2026-05-07].

2026-10-31catalystVIR-5818 response data can test depth of the oncology platformHigh impact

Vir said Phase 1 dose escalation of HER2-targeted VIR-5818 plus pembrolizumab continues and that response data are expected in the second half of 2026, giving investors another oncology readout beyond VIR-5500 while the company builds its masked T-cell engager franchise [#10-Q-2026-05-07].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-08 • Updated nightlySource: Internal modelMethodology